At the 2024 Boao Forum for Asia, AstraZeneca CEO Pascal Soriot shared his positive outlook on the Chinese mainland's economic growth and its increasing role in innovation, particularly within the biopharmaceutical sector.
Soriot highlighted his strong confidence in the efficiency of China's supply chains, emphasizing their strategic importance to AstraZeneca's global operations. This confidence underscores the pivotal role that China plays in supporting AstraZeneca's mission to deliver life-changing medicines to patients around the world.
The discussions at the Boao Forum reflect a broader trend of international collaboration and mutual growth, as global companies like AstraZeneca recognize the value of China's advancements in technology and supply chain management. As China continues to invest in innovation and streamline its supply chains, it stands as a key partner in driving the future of the biopharmaceutical industry.
Reference(s):
cgtn.com
